Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

99 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-10

Study Completion Date

2022-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vaccination against SARS-Cov2 is a necessity for haemodialysis patients because difficulties to maintain a self-isolation (leading to a higher contamination than general population) and an increase of mortality in case of contamination (more than 20% of mortality in this population). However, vaccine efficiency is known to be decreased in haemodialysis patients. This lead critical the rapid description of immunogenicity of anti SARS-Cov2 vaccine in haemodialysis patients.

The aim of this study is to describe the immunogenicity of the BTN162b2 SARS-Cov2 vaccine in haemodialysis patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COVADIAL - Immunogenicity of COVID-19 Vaccine in Hemodialysis Patients

NCT04728828

Covid19

COMPLETED

Safety and Efficacy of the Coronavirus Disease 2019 Vaccine in Hemodialysis Patients

NCT04944433

Coronavirus Disease 2019 Vaccines Renal Dialysis

COMPLETED

"Effects of the Vaccin Against COVID 19 in a Cohort of Dialysis Patients: Adverse Events and Immunological Response"

NCT05055531

COVID Epidemic

UNKNOWN

COVID-19 Infection in Hemodialysis Patients

NCT05069532

COVID-19 Infection in Hemodialysis Patients

UNKNOWN

Protective Antibody Level After COVID-19 Vaccination Among Patients Under Hemodialysis

NCT04871945

Covid19 Vaccine Reaction Hemolysis +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Vaccines Hemodialysis Complication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All haemodialysed patients with a medical prescription of BTN162b2 mRNA Cov-19 vaccine

Serological response is defined by a 4 fold increase of IgG anti-spike protein of SARS-Cov2 between Day 0 (before vaccination) and after complete vaccination (evaluated at Day 7 - 14 post-boost).

Evaluation of the immunogenicity of the vaccine in haemodialysis patients

Intervention Type BIOLOGICAL

The immunogenicity of the vaccine will be evaluated at the peak of vaccine response (Day 7 - Day 14 after the second dose) and 6 and 12 months post vaccination, by the evaluation of humoral IgG anti-spike protein response (seroconversion rate, absolute antibody titers, affinity of antibody) and cellular anti SARS-Cov2 response (number, activation capacity, production of interferon gamma of CD4 and CD8 anti sars cov2 specific T cells)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Evaluation of the immunogenicity of the vaccine in haemodialysis patients

The immunogenicity of the vaccine will be evaluated at the peak of vaccine response (Day 7 - Day 14 after the second dose) and 6 and 12 months post vaccination, by the evaluation of humoral IgG anti-spike protein response (seroconversion rate, absolute antibody titers, affinity of antibody) and cellular anti SARS-Cov2 response (number, activation capacity, production of interferon gamma of CD4 and CD8 anti sars cov2 specific T cells)

Intervention Type BIOLOGICAL